Skip to main navigation
Allogene Therapeutics
Contact Us
Careers
SHARE
Email Us
Print
Allogene Therapeutics
  • About Us
    • At A Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
    • Our Culture
  • AlloCAR T™
    • History of CAR T
    • Next Revolution in Cell Therapy
    • Platform for Tomorrow
    • ALLOGENEIC CELL THERAPY STRATEGY
    • On-demand Availability
  • Pipeline
    • Clinical Trials
    • Expanded Access
    • Scientific Publications
  • Our Culture
    • ESG Report
    • We are one Allogene
    • REVOLUTIONIZING CELL THERAPY
    • DIVERSITY, EQUITY AND INCLUSION
    • JOIN THE ALLOGENE COMMUNITY
  • News Center
    • Events
    • Press Releases
    • Perspectives
    • Our Tweets
    • Media Resources
    • Community Guidelines
  • INVESTORS
    • IR Overview
    • News & Events
      • Press Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
    • Corporate Governance
      • Documents & Charters
      • ESG Report
      • Board of Directors
      • Management
      • Committee Composition
    • SEC Filings
    • Resources
      • Investor FAQs
      • Email Alerts
      • IR Inquiry

Press Releases

Feb 01, 2023
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
SOUTH SAN FRANCISCO, Calif. , Feb. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics , Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, presented preclinical data highlighting the Company’s next generation
Jan 25, 2023
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Preclinical Efficacy and Safety Results Indicate AlloCAR T™ Development Candidate Controls Tumor Growth without Off-Tumor/Normal Tissue Toxicity SOUTH SAN FRANCISCO, Calif. , Jan. 25, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics , Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company
Jan 24, 2023
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple Myeloma SOUTH SAN FRANCISCO, Calif. , Jan. 24, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics , Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company
Jan 17, 2023
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Jan. 17, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor
Jan 04, 2023
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that David Chang , M.D., Ph.D., President, Chief
Jan 03, 2023
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
Cell Therapy Veteran and Former Kite Pharma Clinical Leader to Head Development of Expanding Portfolio of Allogeneic CAR T Product Candidates SOUTH SAN FRANCISCO, Calif. , Jan. 03, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering
Print Page
Email Alerts
RSS Feeds
Investor Contacts
Facebook
Twitter
LinkedIn
E-Mail
Tumblr
Reddit
WhatsApp
Telegram
Allogene Therapeutics
CONNECT

210 E. Grand Avenue
South San Francisco, CA 94080

View Map / Contact Us

  • About Us
  • At a Glance
  • Management Team
  • Board of Directors
  • Scientific Advisors
  • Partners
  • Our Culture
  • ALLOCAR T™
  • History of CAR T
  • Next Revolution in Cell Therapy
  • Platform for Tomorrow
  • Allogeneic Cell Therapy Strategy
  • On-Demand Availability
  • Pipeline
  • Clinical Trials
  • Expanded Access
  • Scientific Publications
  • News Center
  • Events
  • Press Releases
  • Perspectives
  • Our Tweets
  • Media Resources
  • Community Guidelines
  • Investors
  • IR Overview
  • News and Events
    • Press Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Look Up
    • Investment Calculator
  • Corporate Governance
    • Documents & Charters
    • ESG Report
    • Board of Directors
    • Management
    • Committee Composition
  • SEC Filings
  • Resources
  • Investor FAQS
  • Email Alerts
  • IR Inquiry
©2023 Allogene Therapeutics
TERMS OF USE
PRIVACY POLICY
PREFERENCE CENTER